We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £215,946
Receive an affordable massage at home and on-demand by easily booking straight from an app. Since the start of year, Urban Massage has delivered more than 114,000 massages and received a 4.85/5 or above rating for the level of treatment provided to their customers. The company has successfully launched in Birmingham, Manchester and Paris with an Annualised Run Rate (ARR) of 3,300% from June 2014 and in June 2018, an ARR of £10.4m.
days to go: Expired investment: £3,491,730
A highly successful printing business based in the UK, with a £2.3m annual turnover, is now entering the personalised gift market. The YPP Group is launching 'CustomGifts', building upon the company's pre-existing infrastructure and offering next-day delivery with late ordering. Funding will provide development on a mobile website including birthday reminders, as well marketing the service and purchasing required materials and stock.
days to go: Expired investment: £57,780
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £290,278
The Gut Stuff is a proactive advocate for gut health, educating a substantial community and offering an innovative app in BETA that aims to bridge gaps in the gut health market. With a strong presence in physical products, workplace education, and media, they're positioned to redefine the gut health category and leverage diversified revenue streams for growth during their expansion into the digital realm.
days to go: Expired investment: £321,662
33Fuel is a natural sports nutrition brand that aims to dominate sports nutrition with healthier and natural alternatives. Its products consist of ingredients like organic flaxseeds, Tibetan goji berries, organic walnuts, and raw coconuts, to name a few. The company has received over 10,000 orders and multiple 5-star customer reviews. It has 12,000 email subscribers and a podcast with more than 65,000 plays. The company wants to dominate the sports nutrition market that is forecast to reach almost £2 billion by 2024. 33Fuel has attracted superstar shareholders including 4x Ironman Triathlon World Champion Chrissie Wellington and customers such as Tour de France winner Sir Bradley Wiggins. The company has won 'Health Product of the Year' and 'Best Meal Replacement' and has featured in fitness and mainstream media such as The Telegraph, Independent, and Men's Fitness. It will use the investment for marketing to accelerate sales.

Pitch Rated

74%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £367,124
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph